Namibia - English - Namibia Medicines Regulatory Council

glenmark pharmaceuticals south africa (pty) ltd - fluocinolone acetonide , neomycin sulphate - cream - each 1g cream contains fluocinolone acetonide 0,25mg, neomycin sulphate 3500iu

Namibia - English - Namibia Medicines Regulatory Council

glenmark pharmaceuticals south africa (pty) ltd - fluocinolone acetonide , neomycin sulphate - ointment - each 1g ointment contains fluocinolone acetonide 0.25mg , neomycin sulphate 3500 iu

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaceutical company jelfa s.a. - fluocinolone acetonide, neomycin (neomycin sulphate) - ointment for topical use - 0,25mg/g+ 5mg/g

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaceutical company jelfa s.a. - fluocinolone acetonide, neomycin (neomycin sulphate) - ointment for external use - 0,25mg/g+ 5mg/g

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - fluocinolone acetonide; neomycin sulphate -

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide 0.01% topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide 0.01% topical oil needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide 0.01% topical oil should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide 0.01% topical oil should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide 0.01% topical oil should not be used on the face, axillae, or groin unless directed by the physician.  application to intertriginous areas should be avoided due

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide topical oil, 0.01% needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide topical oil, 0.01% should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide topical oil, 0.01% should not be used on the face, axillae, or groin unless directed by the physician. application to intertriginous areas should be avo

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide topical oil is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide topical oil needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide topical oil should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide topical oil should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide topical oil should not be used on the face, axillae, or groin unless directed by the physician. application to intertriginous areas should be avoided due to the increased risk of local adver

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is a low to medium potency corticosteroid indicated: in adult patients for the treatment of psoriasis of the scalp (scalp oil). fluocinolone acetonide 0.01% topical oil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section).

United States - English - NLM (National Library of Medicine)

avkare, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is a low to medium potency corticosteroid indicated: in adult patients for the treatment of psoriasis of the scalp (scalp oil). fluocinolone acetonide 0.01% topical oil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section).